Abstract
Ras association domain family member 5 (RASSF5, also named NORE1) is an identified member of the RASSF gene family which could bind selectively to activate Ras and function as an antineoplastic effector in multiple cellular regulations. While highly expressed in majority of normal tissues, RASSF5 is epigenetically inactivated by promoter hypermethylation in numerous cancer cell lines and primary cancers, suggesting it as a potential tumor suppressor. Nevertheless, the physiologic significance of RASSF5 in tumorigenesis remains unclear. We performed a systematic literature review and assessment from PUBMED and MEDLINE databases in this article. RASSF5 is involved in a series of cellular responses including apoptosis, senescence, cell cycle regulation, differentiation and cell proliferation and the inactivation of RASSF5 has been implicated to participate in the oncogenesis, progression and poor prognosis of human cancers. In this review, we mainly elucidate the acknowledged structure, progress in the verified functions and research advances of RASSF5 and the probably relevant signaling pathways. Based on these evidences, potentiality of RASSF5 as a new therapeutic target for human cancers may play a significant role in future oncotherapy.
Keywords: RASSF5, tumor suppressor, promoter hypermethylation, therapeutic target, malignancy, apoptosis.
Anti-Cancer Agents in Medicinal Chemistry
Title:The Emerging Roles of RASSF5 in Human Malignancy
Volume: 18 Issue: 3
Author(s): Shuofeng Li, Jingwei Teng, Haiqing Li, Feifei Chen*Junnian Zheng*
Affiliation:
- Jiangsu Province Key Laboratory of Biological Cancer Therapy, Xuzhou Medical University, 84 West Huai-hai Road, Xuzhou 221002, Jiangsu,China
- Jiangsu Province Key Laboratory of Biological Cancer Therapy, Xuzhou Medical University, 84 West Huai-hai Road, Xuzhou 221002, Jiangsu,China
Keywords: RASSF5, tumor suppressor, promoter hypermethylation, therapeutic target, malignancy, apoptosis.
Abstract: Ras association domain family member 5 (RASSF5, also named NORE1) is an identified member of the RASSF gene family which could bind selectively to activate Ras and function as an antineoplastic effector in multiple cellular regulations. While highly expressed in majority of normal tissues, RASSF5 is epigenetically inactivated by promoter hypermethylation in numerous cancer cell lines and primary cancers, suggesting it as a potential tumor suppressor. Nevertheless, the physiologic significance of RASSF5 in tumorigenesis remains unclear. We performed a systematic literature review and assessment from PUBMED and MEDLINE databases in this article. RASSF5 is involved in a series of cellular responses including apoptosis, senescence, cell cycle regulation, differentiation and cell proliferation and the inactivation of RASSF5 has been implicated to participate in the oncogenesis, progression and poor prognosis of human cancers. In this review, we mainly elucidate the acknowledged structure, progress in the verified functions and research advances of RASSF5 and the probably relevant signaling pathways. Based on these evidences, potentiality of RASSF5 as a new therapeutic target for human cancers may play a significant role in future oncotherapy.
Export Options
About this article
Cite this article as:
Li Shuofeng, Teng Jingwei , Li Haiqing, Chen Feifei *, Zheng Junnian*, The Emerging Roles of RASSF5 in Human Malignancy, Anti-Cancer Agents in Medicinal Chemistry 2018; 18 (3) . https://dx.doi.org/10.2174/1871520617666170327120747
DOI https://dx.doi.org/10.2174/1871520617666170327120747 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
In vitro Biological Activity Studies of Platinum Group Metal Complexes Containing N, N'- Bis(picolinoyl)hydrazine Ligand
Current Inorganic Chemistry (Discontinued) Crocins: The Active Constituents of Crocus Sativus L. Stigmas, Exert Significant Cytotoxicity on Tumor Cells In Vitro
Current Cancer Therapy Reviews Delivery of Therapeutic Proteins: Challenges and Strategies
Current Drug Targets Differentiation of Non-Pharmacological from Pharmacological Dopamine Release in the Living Human Brain
Current Medical Imaging Three-Dimensional Ultrasound in Gynecology: Current Status and Future Perspectives
Current Women`s Health Reviews Molecular Markers of Glioblastoma and the Potential for Integration with Imaging: the Future for Assigning Prognosis and Best Treatment Strategy
Current Molecular Imaging (Discontinued) Cell Metabolism Under Microenvironmental Low Oxygen Tension Levels in Stemness, Proliferation and Pluripotency
Current Molecular Medicine Osteoinductive Small Molecules: Growth Factor Alternatives for Bone Tissue Engineering
Current Pharmaceutical Design Radiation Dosimetry Aspects of <sup>177</sup>Lu
Current Radiopharmaceuticals Expanding the Biotherapeutics Realm via miR-34a: “Potent Clever Little” Agent in Breast Cancer Therapy
Current Pharmaceutical Biotechnology Epigenetics and Periodontal Disease: Hope to Tame the Untameable
Current Gene Therapy Cancer Stem Cells of Head and Neck Squamous Cell Carcinoma
Current Cancer Therapy Reviews Editorial (Thematic Issue: The Thoracic Space: An Amazing Pandora’s Box!)
Current Respiratory Medicine Reviews Evaluation of Anticancer and Anti-Mitotic Properties of Quinazoline and Quinazolino-Benzothiadiazine Derivatives
Anti-Cancer Agents in Medicinal Chemistry Chronic Myelogenous Leukemia
Current Cancer Therapy Reviews The Prodrugs of 5-Fluorouracil
Current Medicinal Chemistry - Anti-Cancer Agents Interplay of Drug-Metabolizing Enzymes and Transporters in Drug Absorption and Disposition
Current Drug Metabolism Novel In Situ Activity Assays for the Quantitative Molecular Analysis of Neurodegenerative Processes in the Retina
Current Medicinal Chemistry Genetic Variation in SLCO2B1 is Associated with Serum Levels of Testosterone and its Metabolites Prior to and Two Days after Testosterone Administration
Current Pharmacogenomics and Personalized Medicine Carbon Nanotube: A Versatile Carrier for Various Biomedical Applications
Drug Delivery Letters